Abstract
In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 273-291 |
| Number of pages | 19 |
| Journal | Annals of the New York Academy of Sciences |
| Volume | 537 |
| State | Published - Dec 1 1988 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Neuropeptides, dopamine, and schizophrenia. / Nemeroff, Charles; Bissette, G.
In: Annals of the New York Academy of Sciences, Vol. 537, 01.12.1988, p. 273-291.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Neuropeptides, dopamine, and schizophrenia
AU - Nemeroff, Charles
AU - Bissette, G.
PY - 1988/12/1
Y1 - 1988/12/1
N2 - In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.
AB - In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.
UR - http://www.scopus.com/inward/record.url?scp=0024262541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024262541&partnerID=8YFLogxK
M3 - Article
C2 - 3059929
AN - SCOPUS:0024262541
VL - 537
SP - 273
EP - 291
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
SN - 0077-8923
ER -